Insulin Resistance: A Proinflammatory State Mediated  
                        by Lipid-Induced Signaling Dysfunction and Involved in Atherosclerotic Plaque Instability by Montecucco, Fabrizio et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2008, Article ID 767623, 10 pages
doi:10.1155/2008/767623
ReviewArticle
Insulin Resistance: A Proinﬂammatory State Mediated
by Lipid-Induced Signaling Dysfunction and Involved in
Atherosclerotic Plaque Instability
Fabrizio Montecucco, Sabine Steffens, and Franc ¸oisMach
Division of Cardiology, Foundation for Medical Researches, University Hospital, 1211 Geneva, Switzerland
Correspondence should be addressed to Franc ¸ois Mach, francois.mach@medecine.unige.ch
Received 5 February 2008; Accepted 9 June 2008
Recommended by Fulvio D’Acquisto
The dysregulation of the insulin-glucose axis represents the crucial event in insulin resistance syndrome. Insulin resistance
increases atherogenesis and atherosclerotic plaque instability by inducing proinﬂammatory activities on vascular and immune
cells. This condition characterizes several diseases, such as type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting
glucose (IFG), obesity, hypertension, dyslipidemia, and other endocrinopathies, but also cancer. Recent studies suggest that the
pathophysiology of insulin resistance is closely related to interferences with insulin-mediated intracellular signaling on skeletal
muscle cells, hepatocytes, and adipocytes. Strong evidence supports the role of free fatty acids (FFAs) in promoting insulin
resistance. The FFA-induced activation of protein kinase C (PKC) delta, inhibitor kappaB kinase (IKK), or c-Jun N-terminal
kinase (JNK) modulates insulin-triggered intracellular pathway (classically known as PI3-K-dependent). Therefore, reduction of
FFA levels represents a selective target for modulating insulin resistance.
Copyright © 2008 Fabrizio Montecucco et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. EPIDEMIOLOGY OF INSULIN RESISTANCE
Historically, the sweetness of urine and other body ﬂu-
ids in diabetic patients suggested that glucose had an
important role in the physiopathology of this common
disease. Thus, glucose metabolism and the insulin-glucose
axis were the leading ﬁelds for scientiﬁc investigations. To
emphasize this concept, diabetes was called “mellitus.” Not
only hyperglycaemia is crucial for the diagnosis of diabetes
and the development of clinical complications [1], but also
increasing evidence demonstrated the involvement of insulin
in the physiopathology of this disease. In fact, diabetes is a
metabolic disease characterized by hyperglycaemia resulting
from either defects in insulin secretion or insulin properties,
or both. In the present review, we focus on defects of insulin
properties,withparticularregardtoinsulinresistance,which
c a nb ed e ﬁ n e da sas t a t eo fr e d u c e dr e s p o n s i v e n e s st on o r m a l
circulating levels of insulin. This condition is a feature of
various disorders, such as type 2 diabetes, which may range
from predominantly insulin resistance with relative insulin
deﬁciency to a predominatly secretory defect of insulin [1].
Insulin resistance is also implicated in impaired glucose
tolerance (IGT) or impaired fasting glucose (IFG), both
considered as “prediabetes” by the Expert Committee on the
Diagnosis and Classiﬁcation of Diabetes Mellitus [2–4], as
well as in obesity, hypertension, dyslipidaemia (all disorders
clustering in the so-called metabolic syndrome) [5], other
endocrinopathies [6], but also in diﬀerent diseases, such as
cancer, infections or rheumatic, and autoimmune diseases
[7–11]. Therefore, given the association between insulin
resistance and diﬀerent diseases, no epidemiological data are
available, speciﬁcally focused on insulin resistance syndrome
prevalence or incidence. Furthermore, only recently (in
1997) the WHO have accepted obesity as an epidemic public
health burden in adults, without evaluating a well-deﬁned
method to monitoring the problem in children [12–15].
Finally, still few clinical studies on Asian and African cohorts
focused on insulin resistance and related diseases have been
published [16–19]. For all these reasons, to better deﬁne
insulin resistance epidemiology syndrome requires more
investigations. Mechanisms of insulin resistance remain also
unknown. Insulin resistance was initially recognized as an2 Mediators of Inﬂammation
“allergy” to insulin, with the production of antibodies
anti-insulin [20, 21]. Further investigations showed that
metabolism of both nonesteriﬁed fatty acids (NEFA) and
free fatty acids (FFAs) was a crucial step in the development
of insulin resistance [22, 23]. On the basis of these new
evidences, Shafrir and Raz suggested in 2003 that diabetes
should be now called “lipidus” instead of “mellitus” [24].
Given the importance of physiological eﬀects of insulin
during atherogenesis [25–27], there is a need to better clarify
the complexity of mechanisms underlying insulin resistance.
2. MECHANISMS OF INSULIN RESISTANCE
Insulin is an anabolic essential hormone for the maintenance
of glucose omeostasis, tissue growth, and development [28].
It is well known that insulin is secreted by the pancreatic β
cells mainly in response to increased blood levels of glucose
and aminoacids after the meals (extrinsic rhythm) [29]. In
addition, the concentration of insulin in the blood displays
regular variations independently from the food intake [30].
In fact, two rhythms with periods of 5–10 minutes and 60–
120 minutes have been documented (intrinsic rhythm) [31–
33]. The extrinsic rhythm was found altered in a lot of
diseases including gestational diabetes [34], maturity onset
diabetes of the young (MODY) 1 [35, 36], MODY 3 [37],
and Chagas’ disease [38]. Furthermore, an altered plasma
insulin secretory response has been also observed as an
eﬀect of aging processes [39]. On the contrary, the intrinsic
rhythm has been found altered in various diseases, such
as type 2 diabetes (i.e., MODY 2 as well as maternally
inherited diabetes and deafness (MIDD)) [40, 41], obesity
[42], and hypertension [43]. Several genetic and molecular
studies have been performed to investigate the causes of
the dysregulated plasma insulin pattern. Although genetic
mutationsaccountforaminorroleinthelargepartofinsulin
resistance, an alteration of insulin signal transduction, which
may be due to genetic mutations, could contribute to
the impairment of insulin secretory proﬁle and insulin
resistance. Thus, mutations of glucokinase phosphorylated
glucose, hepatic nuclear factor-4 alpha, hepatic nuclear
factor-1 alpha, mitochondrial tRNALeu(UUR), and also
insulin receptor genes have been found [35, 37, 44–46].
For instance, a mutation in the insulin receptor gene of
the pancreatic β cells has been correlated with a defective
insulin-mediated intracellular signal transduction [46]. On
the other hand, obesity and increased FFA levels mediate
insulin resistance by inducing a decreased IRS-1-associated
phosphatidylinositol 3-kinase (PI3-K) activity [47]. In line
with these ﬁndings, it has been shown that insulin resistance
was reversed when obese persons lose weight [48]. However,
this weight loss did not restore normal insulin pulsatiliy in
Type 2 diabetes patients [49]. These data suggest that the
defective insulin-mediated intracellular signal transduction
is not the only cause responsible for insulin resistance, and
that the molecular mechanisms of insulin resistance are not
completely understood. We will discuss in the following
the potential mechanisms contributing to insulin resistance
which are currently under investigation.
2.1. Defectsoninsulinsignaling
The insulin receptor is considered to play a critical role in
insulin resistance. It is a member of the receptor tyrosine
kinase family [50], composed of two α-subunits and two β-
subunits linked together by disulphide bonds. Two isoforms
of insulin receptors are known, exhibiting diﬀerent aﬃnity
for insulin and distribution within tissues. Although it is
tempting to suggest that diﬀerences in binding activity could
contribute to insulin resistance, experimental evidence for
t h ei n v o l v e m e n to fr e c e p t o ri s o f o r m so rr e c e p t o rh y b r i d s
remains controversial [29]. Apart from the insulin binding
step to its receptor, the receptor intracellular tyrosine
kinase domains (capable of intrinsic kinase activity) have
been investigated in view of their possible implication in
insulinresistance.Avarietyofscaﬀoldingproteins,including
insulin receptor substrate (IRS) proteins, casitas B lineage
lymphoma (Cbl), or Cbl associated protein (CAP), bind to
intracellular receptor sites and become phosphorylated [51–
53].IRS-1and-2areconsideredthemostimportantproteins
in regulation of glucose metabolism [54]. As shown in
knockout mouse models, IRS-1 or IRS-2 inactivation causes
insulin resistance [55, 56]. In addition, in vitro experiments
showed an increased serine phosphorylation of IRS by
tumor necrosis factor-alpha (TNF-α) or FFA stimulation,
thereby causing impaired insulin signal transduction [54,
57]. Finally, a prolonged exposure to insulin (a typical
condition in hyperinsulinemic patients) may result in a
degradation of IRS protein [58]. All together, these data sup-
portIRS-1andIRS-2ascrucialplayersinthedevelopmentof
insulin resistance. Furthermore, numerous studies aimed to
identify downstream elements of IRS proteins in the insulin-
mediated signal transduction pathway. As mentioned above,
PI3-Kisconsideredthecentralmediator[59].Threediﬀerent
isoforms of this kinase have been identiﬁed: Ia, PI3-K/Akt,
capable of generating phosphatidylinositol 4,5-bisphosphate
(PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3);
Ib, G protein regulated kinase; II, incapable of generating
PIP2 and PIP3. As shown in Figure 1(a), activated PI3-K
is responsible for the beginning of a complex phosphory-
lation cascade, involving the phospholipids PIP2, PIP3, the
phosphoinositide-dependent kinase 1 (PDK1), the protein
kinase B (PKB, also called Akt), as well as the protein
kinase C (PKC). Akt mediates the eﬀects of insulin on
glucose transport (GLUT) [60], glycogen synthesis, protein
synthesis, lipogenesis, and suppression of hepatic gluco-
neogenesis [59]. Once activated, Akt detaches from the
plasma membrane and translocates into the nucleus through
a still unknown mechanism [61], or activates diﬀerent
substrates, such as glycogen synthase kinase-3 (GSK-3) and
transcription factors of the Foxo-family [59]. All these
proteins and phospholipids are likely to be implicated in
insulin resistance. For instance, a reduced PI3-K activity has
been reported in skeletal muscle and adipocytes of patients
with insulin resistance [62–64]. In addition, Akt activation
has been found reduced in several diseases associated with
insulin resistance [65, 66]. However, Akt involvement in
insulin resistance is controversial, since other studies did not
show any alteration of Akt activation in insulin resistanceFabrizio Montecucco et al. 3
(a) Molecular mechanism involved
in insulin resistance
(b) Main cell types involved in the
development of insulin resistance
(c) Main cell types activated by hyperinsulinemia
in atherosclerotic inﬂammatory processes
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Figure 1: Lipid signaling interference generates insulin resistance. (a) Signaling through phosphatidylinositol 3-kinase (PI3-K) is crucial
for insulin-mediated glucose transport in hepatocytes and skeletal muscle cells and for inﬂammatory protein and hormone secretion in
adipocytes and pancreatic β cells. Free fatty acids (FFAs) induce a defective insulin-mediated signaling mainly through the activation of
protein kinase C (PKC θ), inhibitor κB kinase (IKK) and c-Jun N-terminal kinase (JNK). (b) Main cell types involved in the development of
insulin resistance. (c) Main inﬂammatory cell populations involved in hyperinsulinemia-induced inﬂammatory states.
associated syndromes [67, 68]. On the other hand, insulin-
induced PKC activation has been found altered in type 2
diabetic [69] or obese [70] patients. Therefore, although
other studies are needed, all these observations suggest that
a reduction of insulin-mediated intracellular signaling is
crucial for the establishment of insulin resistance.
Anotherpossiblemechanismleadingtoinsulinresistance
might be an upregulation of protein-tyrosine phosphatases
(PTPases), capable of functioning as negative regulators
of the insulin-triggered pathway. Among various proteins,
PTP 1B has been shown as a key regulator of insulin
signaling [71–73]. Other phosphatases, such as ectonu-
cleotide pyrophosphatase phosphodiesterase 1 (ENPP1, also
known as PC-1), SH-2-containing inositol 5 -phosphatase 2
(SHIP2), and phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) have been shown to interfere with
insulin sensitivity [74–76]. Although further investigations
are warranted to very verify these hypotheses, these proteins
may represent future potential targets for the treatment of
insulin resistance.
2.2. Glucosemetabolism
Glucoseuptakeintomuscleandfattissuedependsonglucose
transporter 4 (GLUT4) expression on the cell membrane.
Insulin reduces glycaemia, mainly by inducing the secretion
o ft h i sm o l e c u l eb ym u s c l ea n df a tc e l l s[ 77]. However,
GLUT4 polymorphisms or mutations inactivating GLUT4
gene were not associated with insulin resistance [78]. In
addition, GLUT4concentrations in skeletal muscle of insulin
resistant patients were not reduced [79]. This suggests that
alterations in GLUT4 expression are not a primary cause
for the development of insulin resistance. In this context,
the correct functioning of insulin intracellular signalization
appears essential. In fact, GLUT4 upregulation represents
the ﬁnal event of insulin signaling cascade [80–82]. Among
various kinases (Figure 1(a)), Aktβ has been shown to play
an essential role. Recently, in vitro and in vivo studies
suggested that PKBβ alterations [83] or disruption [84]a r e
responsible for the reduction of insulin-induced glucose
uptake. Consistent with these data, recent studies in humans
detected a missense mutation in the kinase domain of PKBβ
(Akt 2) associated with severe insulin resistance [85]. These
data suggest that insulin signaling also plays crucial role in
the regulation glucose homeostasis.
2.3. Inﬂammatorymolecules
Recent evidence suggests that inﬂammation might be crucial
for the development of insulin resistance [86]. Proinﬂam-
matory cytokines and acute-phase reactants are positively
correlated with insulin resistance in metabolic syndrome
patients [87]. Among these soluble mediators, interleukin
(IL)-1 and IL-1 receptor antagonist (RA) have been impli-
cated in the development of insulin resistance in humans
[88, 89] and in rodents [90, 91]. IL-1RA is anaturally
occurring cytokine and a member of the IL-1 family whose
only function is to prevent a biologic response to IL-
1[ 92]. In humans, the blockade of IL-1 with IL-1 RA
improves glycaemia and beta-cell secretory function and
reduces markers of systemic inﬂammation [93]. Accordingly,
IL-1 has been shown to induce insulin resistance mainly4 Mediators of Inﬂammation
by inhibiting insulin-mediated signaling [94, 95]. Thus, IL-
1 has to be considered as an important factor involved in
insulin resistance. TNF-α and IL-6 are also of particular
interest, because of their increased expression in adipose
tissue and their capacity to induce insulin resistance [96].
Further evidence for the link between TNF-α and insulin
resistance was provided by a study using blocking anti-TNF-
α antibodies in obese rodents or TNF-α knockout obese
mice [97]. In these animals, a reduced insulin resistance
was obtained by the suppression of TNF-α. The possible
molecular mechanism of TNF-α-induced insulin resistance
may involve IRS-1 [98]. Surprisingly, the infusion of anti-
TNF-α antibody in humans did not aﬀect insulin resistance.
Further investigations are needed to better understand these
opposite results obtained in human and mice. On the
other hand, the role of IL-6 in insulin resistance is also
controversial. IL-6 interferes with the metabolism of both
adipose and skeletal muscle tissues [99, 100], but has also a
positiveeﬀectonskeletalmusclecellinsulinsensitivity[101].
In addition, IL-15 has been shown to play a possible role in
myocyte-adipocyte crosstalk, but only few studies are pub-
lished at present to better clarify its role in insulin resistance
[102]. Moreover, it is now established that hormones from
adipose tissue hormones contribute to insulin resistance. For
instance, leptin has been shown to reverse insulin resistance
in mice with congenital lipodystrophy [103]. Administration
ofleptintopatientswithlipodystrophycanincreasethebody
fat content and reverse insulin resistance [104]. Resistin, a
new adipocyte hormone [105], may be another important
link between increased fat mass and insulin resistance [106].
Resistin decreases insulin-dependent glucose transport in
vitro and increases fasting blood glucose concentrations and
hepatic glucose production in vivo [106–109]. Similarly,
the reduction of adiponectin could contribute to insulin
resistance. Very recently, adiponectin has been showed as
an anti-inﬂammatory and immunomodulatory molecule
[110, 111]. In humans, adiponectin levels correlate with
insulin sensitivity. Mice deﬁcient in adiponectin are insulin
resistant [112] and the administration of adiponectine to
obese and insulin resistant mice has been shown to improve
insulin sensitivity [113–115]. In addition, inﬂammatory
mediators such as the proinﬂammatory chemokine mono-
cyte chemotactic protein-1 (MCP-1) are believed to play
a role in the pathogenesis of insulin resistance. Recent in
vitroevidencesuggeststhatMCP-1inducesinsulinresistance
in both adipocytes and skeletal muscle cells [116]. Finally,
retinol-binding protein (RBP)-4 and tissue inhibitors of
metalloproteinases (TIMP)-1 were recently described to
contribute to insulin resistance in vivo, but the underlying
mechanism remains unclear [117–119]. In conclusion, at
the present state of knowledge, insulin resistance has to be
deﬁned as a complex syndrome involving not only glucose
and lipids, but also several proinﬂammatory molecules.
2.4. Lipidsandinsulinresistance
Lipid abnormalities, such as increased circulating free fatty
acids, are frequently associated with insulin resistance [120].
Lipid metabolism induces insulin resistance through a well-
known cascade of events. The excessive fat intake causes
an increased inﬂux of triglycerides into the blood and
an excess of plasma levels of FFAs, which induce insulin
resistance, with consequent hyperglycaemia. The increased
levels of glucose stimulate pancreatic β cells to secrete
more and more insulin, generating hyperinsulinemia, which
further triggers the elevation of triglycerides and closes the
v i c i o u sc i r c l e[ 121]. When insulin secretion is not suﬃcient
and elevated glucose levels prevail, diabetes becomes overt.
Defective insulin secretion is a result of chronic exposure
to elevated levels of fatty acids, which inhibits insulin gene
expression by functioning as true toxic agents for pancreatic
β cells [122]. “Lipotoxicity” depends on the interference
with insulin-mediated intracellular signaling in various cell
types (Figure 1). In particular, FFAs have been shown to
activate PKC θ (Figure 1(a)), which not only interferes with
insulin signaling (by inducing insulin resistance), but also
is implicated in promoting proatherogenic mechanisms,
such as endothelial dysfunction, growth, migration, and
apoptosis of vascular smooth muscle cells, induction of
adhesion molecules and oxidized low-density lipoprotein
uptake of oxidized low-density lipoprotein by monocyte-
derived macrophages [123]. Furthermore, it was recently
shown that FFAs induce insulin resistance in muscle through
the activation of inhibitor κB kinase (IKK) and c-Jun N-
terminal kinase (JNK) (Figure 1(a)) [124]. Therefore, FFAs
induce insulin resistance in hepatocytes and skeletal muscle
cells through the activation of diﬀerent kinases (Figures
1(a) and 1(b)). Both FFAs from plasma and those released
from stored triglycerides activate second messangers, which
alter insulin signaling [125]. FFAs are also involved in
modulating insulin production by pancreatic β-cells and
cytokine secretion by hepatocytes, adipocyte, muscle cells,
and inﬂammatory cells (Figure 1(c)). This strongly supports
FFA as important proatherosclerotic agents.
3. ROLE OF INSULIN RESISTANCE IN
ATHEROSCLEROTIC PLAQUE INSTABILITY
The development of atherosclerotic plaques is dependent
on the interaction of multistep biochemical processes that
lead to the plaque formation, maturation, and complica-
tion [126]. Plaque instability, rupture, and thrombosis are
crucial events in the acute artery occlusion, which causes
dramatic ischemic consequences in the heart, brain, and
also peripheral tissues. Insulin resistance is considered to
be a pivotal event in the increased risk of plaque instability
through diﬀerent pathways [127, 128]. High concentrations
of insulin directly increase proinﬂammatory activities of
leukocytes, which are involved in atherosclerotic plaque
instability. In particular, insulin directly increases neutrophil
and monocyte in vitro migration in response to chemokines
secreted in atherosclerotic plaques [129, 130]. Insulin could
also favor atherosclerotic plaque necrosis by accelerating
macrophage death [131]. Furthermore, insulin induces in
vivo production of matrix metalloproteinase-9 (MMP-9),
which is responsible for plaque instability and rupture
[132–134]. The pharmacologic or behavioral treatments
to reduce insulin resistance have been shown to inhibitFabrizio Montecucco et al. 5
MMP-9 secretion [126, 135, 136]. On the other hand,
insulin could also induce a serious atherothrombotic state,
by increasing platelet resistance to antiaggregating agents
[137] and production of procoagulatory factors, such as
plasminogen activator inhibitor-1 (PAI-1), factor VII, factor
XII, ﬁbrinogen, and tissue plasminogen activator [126].
These evidences strongly support an emerging role of insulin
in plaque instability and rupture. Further investigations are
needed to better clarify the speciﬁc roles and the interactions
of insulin and lipids on inﬂammatory cells.
4. CONCLUSIONREMARKS
In the last years, the standard deﬁnition of insulin resistance
has been shifted from a traditional “glucocentric” to a
new “lipocentric” view [138]. Several soluble mediators are
involved in the development of insulin resistance, through
generating insulin signaling dysfunction. Among these,
FFAs have to be considered as proatherosclerotic agents,
capable of interfering with insulin signaling and provoking
insulin resistance. New and selective therapies contrasting
FFA eﬀects may be promising targets for the treatment of
insulin resistance. A possible promising strategy capable of
reducing the consequences of excessive lipolysis and reorient
FFA ﬂux toward adipose tissue might be represented by
peroxisome proliferator-activated receptor (PPAR)-α and -
γ agonists [139]. PPAR-γ agonists have been recently shown
to regulate trygliceride lipase in adipocytes in vitro and
in vivo [140]. Furthermore, PPAR-γ has been shown as
crucial in the control of diﬀerentiation of human monocytes
in M2 macrophages, the subset of macrophages resident
in atherosclerotic plaques with anti-inﬂammatory activity
[141]. In vivo studies have also demonstrated that PPAR-γ
agonists treatment in patients with type 2 diabetes mellitus
is associated with a reduction in plasma NEFA levels [142–
145]. However, two recent important clinical studies have
shown an increase of acute cardiovascular outcomes induced
by treatment with thiazolidinediones (PPAR-γ agonists)
[146, 147]. On the other hand, although PPAR-α has been
shown to have vascular and metabolic beneﬁcial eﬀects,
the activity of PPAR-α agonists on lipid metabolism is still
controversial [148, 149]. Therefore, further trials are needed
to recommend the use of these pharmacological agents for
reducing lipid-mediated insulin resistance.
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